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The association between diabetes and cardiovascular diseases is well estab-
lished, as still the main cause of death among these patients. We followed a
cohort of 703 high risk type 2 diabetic patients during a median follow up of
5,8 years and thought to determine predictive factors associated with mortality
and cardiovascular mortality.
Methods: Survival analysis was made. For univariate analysis, we used
Kaplan Meyer methods. Covariables with p-value < 0.15 at log-rank test were
introduced in COX multivariate analysis. Significant variables were selec-
tioned for final model selection through STEPWISE, BACKWARD, FOR-
WARD methods.
Results: Among these patients, 58% were male, mean age of 62,06 years,
with a mean length of diabetes of 13,80 years and a HbA1c of 8,35%. 29%
had positive microalbuminuria or proteinuria, 14% had a creatinin clearance
inferior to 60 ml/min. 12% had obliterating arteriopathy of the lower limbs
definied by pulse abolition. Mean LDL was 1,10 g/l, 54% of these patients
were under statin treatment. 60% were classified as having hypertension, and
43% were currents somokers. During follow up, 67 patients died (9,5%) with
mainly cardiovascular death (57 patients). In multivariate analysis, obliterating
arteriopathy of the lower limbs, insulin treatment, antiagregant treatment,
triglyceride level above 1,5 g/l were associated with global mortality.
Regarding predictive factors associated with cardiovascular mortality, we
found that obliterating arteriopathy of the lower limbs, creatinin clearance under
60 ml/min and high systolic blood pressure were associated. Obliterating arte-
riopathy of the lower limbs was the strongest predictor of mortality (RR=2,68;
IC95%:1,58-4,52) and of cardiovascular mortality (RR=2,79; IC95%:1,68-
4,64).
Conclusion: Presence of obliterating arteriopathy of the lower limbs diag-
nosed by clinical examination was the strongest factor associated with global
and cardiovascular mortality in high risk type 2 diabetic patients.
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The aims of this study were in obese patients to evaluate the role of predi-
abetes in LVH before bariatric surgery and in the changes of LV mass after
surgery.
Research methods: Echocardiography was performed in 107 obese
patients. After exclusion of 34 patients due to diabetes or obstructive sleep
apnea and 4 patients with a poor quality imaging, 69 echocardiographies could
be analysed: 55 women and 14 men, age 35.6±11.1 years, mean BMI
43.3±4.8 kg/m², mean blood pressure 121/71 mmHg. An oral glucose tolerance
test (OGTT) was performed in these patients.
Results: Prediabetes was diagnosed in 32% of the patients, and 50% had
insulin resistance as defined by HOMA-IR >3. Nine patients (13%) had
LVH (LV mass (LVM) indexed on height: LVM/h >1.21 g/m² in women and
1.63 g/m² in men). LVM correlated with fat-free mass (p<0.001), waist/hip
ratio (p<0.001), fasting plasma glucose and 2-h OGTT glucose (p=0.015 and
0.045). In multivariate regression analysis LVM/h was still associated with
2h OGTT glucose. LVM/h was significantly higher in patients with pre-
diabetes and/or insulin resistance (p=0.013). Echocardiographic parameters
were again measured in 26 patients 6 to 50 months (mean 17.6) after bari-
atric surgery (modulable banding gastroplasty 52%, sleeve-gastrectomy 33%
and by-pass 15%), which induced a mean weight loss of 22.8%. Changes in
LVM correlated weakly with body weight changes (p=0.04), glucose tole-
rance was normalized in 4 of 8 patients with prediabetes. LVH persisted in
4 out of 8 patients. Half patients who increased their LVM were prediabetic
preoperatively whereas all the patients who reduced their LVM (– 14% in
means) were normoglycemic preoperatively (p=0.03). LVM changes were
associated significantly with body weight changes and glycemic status at
inclusion.
Conclusion: prediabetes is a determinant factor of LVM and its post-sur-
gical change. Weight loss after surgery is associated with LVM decrease only
in patients with a normal glucose tolerance.
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Objective: we investigated in 715 men aged 45-74 with stable coronary
artery disease (CAD) and 782 controls whether serum adiponectin was asso-
ciated with long-term total and cardiovascular diseases (CVD) mortality,
considering varying degrees of CAD severity.
Methods and results: adiponectin was lower in patients (5.6±0.2 µg/mL)
than in controls (7.1±0.2 µg/mL), (p<0.001) but became similar after mul-
tivariate adjustment (6.1±0.3 µg/mL) and (6.5±0.3 µg/mL) respectively
(p=0.17). During a median follow-up of 8.1 years, survival rates among
CAD patients in increasing quartiles of serum adiponectin values were
87.5%, 85.6%, 76.4% and 67.6%, respectively (p<0.001 by log-rank test).
Survival rates in controls with adiponectin <9.1 µg/mL and ≥9.1 µg/mL
(third quartile) were 95.3% and 91.0% respectively (p=0.035 by log-rank
test). Adiponectin concentration above the highest quartile was associated
with an increased risk of all-cause and cardiovascular mortality in CAD
patients (p=0.001 and p=0.001 respectively) and in controls (p=0.03 and
p=0.01 respectively). An increase of 1 µg/mL of adiponectin was associ-
ated with an increased risk of total mortality of 8.0% (HR= 1.08 [95% CI
1.05-1.11], p<0.001) in the whole population, combining both CAD
patients and controls. The associations between high adiponectin and total
or cardiovascular mortality remained significant after multivariate adjust-
ment.
Conclusion: high serum adiponectin is a powerful predictor of mortality
particularly from CVD. This prognostic value remains significant whatever
the severity of the CAD and is not different among people with and without
CAD.
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